Publications:

Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status.

Cell Death & Disease

Das, Ishani I; Wilhelm, Margareta M; Höiom, Veronica V; Franco Marquez, Rodolfo R; Costa Svedman, Fernanda F; Hansson, Johan J; Tuominen, Rainer R; Egyhàzi Brage, Suzanne S

Publication Date: 2019-09-10

Variant appearance in text: IGF1R: 485A>T; Asp162Val

PubMed Link: 31506424

Variant Present in the following documents:

• 41419_2019_1875_MOESM2_ESM.pdf

View BVdb publication page